Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver

Rosiglitazone, a synthetic peroxisome proliferator-activated receptor γ (PPARγ) ligand, has been reported to reduce growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in 10 patients with acromegaly. However, the mechanisms remain unknown. Here, we reveal that PPARγ directly enhances 15-hyd...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yichao, Wang, Meng, Ji, Chenxing, Chen, Zhengyuan, Yang, Hui, Wang, Lei, Yu, Yifei, Qiao, Nidan, Ma, Zengyi, Ye, Zhao, Shao, Xiaoqing, Liu, Wenjuan, Wang, Yi, Gong, Wei, Melnikov, Vladimir, Hu, Lydia, Lee, Eun Jig, Ye, Hongying, Wang, Yongfei, Li, Yiming, He, Min, Zhao, Yao, Zhang, Zhaoyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403734/
https://www.ncbi.nlm.nih.gov/pubmed/34485865
http://dx.doi.org/10.1016/j.isci.2021.102983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403734/
https://www.ncbi.nlm.nih.gov/pubmed/34485865
http://dx.doi.org/10.1016/j.isci.2021.102983

Ejemplares similares